National Transfusion Treatment Survey in Patients With Sickle Cell Disease (SCD)

About the study

The “National Transfusion Treatment Survey in patients with sickle cell disease (SCD)” is a prospective longitudinal systemic study that was created in order to evaluate the therapeutic approach, mainly transfusional, in patients affected by SCD throughout Italy and to improve the quality of care and implement research.

The survey will evaluate all patients affected by different forms of sickle cell disease (HbS homozygosis, Thalassoso-drepanocytosis, HbS / HbC compound heterozygosis, other possible genetic compounds).

Patients will be selected according with a SCD diagnosis confirmed by standardized biochemical criteria or by DNA analysis. Patients will be excluded from the study who do not meet the these requirements, who are unable to understand the protocol or able to give informed consent in the absence of any legal representative.

All data will be collected through a standard web-based application, which will be completed by the responsable investigator or by sub-investigators selected by each center, after registration on the site providing personal data and indicating the affiliation structure. All data will be subsequently encrypted by the Central Server. The operator will subsequently be able to access the patient’s clinical data to perform the updates, in order to follow the patient’s clinical evolution over time. The study will not involve any additional tests compared to the routine of patient control.

Study point of contact

Forni, MD
+39 010 5634560
[email protected]
+39 010 5634560
[email protected]



Study type






participation requirements

patients suffering of sickle cell disease, with diagnosis confirmed by standardized biochemical criteria or by matching mutations on globin genes by DNA analysis;
all patients who consent to the study by signing the informed consent given by the U.O.C.

participation restrictions

patients without a diagnosis confirmed according to standardized biochemical criteria or via mutation on globin genes by DNA analysis.
all patients unable to understand the study protocol and to give informed consent and who have no legal representative.

Last updated 2022-05-04